Format

Send to

Choose Destination
Oncoimmunology. 2015 Mar 16;4(7):e1011527. eCollection 2015 Jul.

Antileukemia T-cell responses in CLL - We don't need no aberration.

Author information

1
Institute for Cell Biology; Department of Immunology; University of Tübingen; Tübingen , Germany.
2
Institute for Cell Biology; Department of Immunology; University of Tübingen; Tübingen , Germany ; German Cancer Consortium (DKTK), DKFZ Partner Site ; Tübingen, Germany.
3
Department of Hematology and Oncology; University of Tübingen ; Tübingen, Germany.

Abstract

Effective antigen-specific cancer immunotherapy requires exact knowledge of tumor-associated epitopes that can act as rejection antigens. Although the current paradigm views mutation-derived neoantigens as the most promising targets, we have recently demonstrated that leukemia-specific T-cell responses associated with survival benefit in CLL patients target a panel of non-mutated tumor-associated antigens.

KEYWORDS:

cancer immunotherapy; chronic lymphocytic leukemia; neoantigen; tumor-associated antigen

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center